Logo image of VERV

VERVE THERAPEUTICS INC (VERV) Stock Fundamental Analysis

NASDAQ:VERV - Nasdaq - US92539P1012 - Common Stock - Currency: USD

4.455  -0.16 (-3.36%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VERV. VERV was compared to 561 industry peers in the Biotechnology industry. VERV has a great financial health rating, but its profitability evaluates not so good. VERV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

VERV had negative earnings in the past year.
VERV had a negative operating cash flow in the past year.
In the past 5 years VERV always reported negative net income.
VERV had a negative operating cash flow in each of the past 5 years.
VERV Yearly Net Income VS EBIT VS OCF VS FCFVERV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

VERV has a better Return On Assets (-30.69%) than 65.06% of its industry peers.
Looking at the Return On Equity, with a value of -40.27%, VERV is in the better half of the industry, outperforming 69.70% of the companies in the same industry.
Industry RankSector Rank
ROA -30.69%
ROE -40.27%
ROIC N/A
ROA(3y)-26.82%
ROA(5y)-34.01%
ROE(3y)-34.07%
ROE(5y)-42.09%
ROIC(3y)N/A
ROIC(5y)N/A
VERV Yearly ROA, ROE, ROICVERV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VERV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VERV Yearly Profit, Operating, Gross MarginsVERV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

VERV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VERV has been increased compared to 1 year ago.
The number of shares outstanding for VERV has been increased compared to 5 years ago.
There is no outstanding debt for VERV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VERV Yearly Shares OutstandingVERV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VERV Yearly Total Debt VS Total AssetsVERV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

VERV has an Altman-Z score of -0.19. This is a bad value and indicates that VERV is not financially healthy and even has some risk of bankruptcy.
VERV has a Altman-Z score of -0.19. This is in the better half of the industry: VERV outperforms 63.64% of its industry peers.
VERV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.19
ROIC/WACCN/A
WACC9.9%
VERV Yearly LT Debt VS Equity VS FCFVERV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

VERV has a Current Ratio of 12.65. This indicates that VERV is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 12.65, VERV belongs to the best of the industry, outperforming 85.03% of the companies in the same industry.
A Quick Ratio of 12.65 indicates that VERV has no problem at all paying its short term obligations.
The Quick ratio of VERV (12.65) is better than 85.03% of its industry peers.
Industry RankSector Rank
Current Ratio 12.65
Quick Ratio 12.65
VERV Yearly Current Assets VS Current LiabilitesVERV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

VERV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.48%, which is quite impressive.
VERV shows a strong growth in Revenue. In the last year, the Revenue has grown by 174.98%.
EPS 1Y (TTM)26.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.68%
Revenue 1Y (TTM)174.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%479.03%

3.2 Future

VERV is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.01% yearly.
Based on estimates for the next years, VERV will show a decrease in Revenue. The Revenue will decrease by -6.18% on average per year.
EPS Next Y-10.2%
EPS Next 2Y-9.79%
EPS Next 3Y-3.1%
EPS Next 5Y-8.01%
Revenue Next Year41.43%
Revenue Next 2Y-26.34%
Revenue Next 3Y-16.91%
Revenue Next 5Y-6.18%

3.3 Evolution

VERV Yearly Revenue VS EstimatesVERV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
VERV Yearly EPS VS EstimatesVERV Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VERV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VERV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VERV Price Earnings VS Forward Price EarningsVERV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VERV Per share dataVERV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

VERV's earnings are expected to decrease with -3.10% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.79%
EPS Next 3Y-3.1%

More info and screens

0

5. Dividend

5.1 Amount

VERV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERVE THERAPEUTICS INC

NASDAQ:VERV (5/21/2025, 11:18:10 AM)

4.455

-0.16 (-3.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)N/A N/A
Inst Owners94.41%
Inst Owner Change4.25%
Ins Owners5.24%
Ins Owner Change0.25%
Market Cap397.12M
Analysts83.75
Price Target25.67 (476.21%)
Short Float %21.89%
Short Ratio5.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.66%
Min EPS beat(2)17.01%
Max EPS beat(2)18.3%
EPS beat(4)4
Avg EPS beat(4)17.4%
Min EPS beat(4)15.43%
Max EPS beat(4)18.87%
EPS beat(8)7
Avg EPS beat(8)13.98%
EPS beat(12)9
Avg EPS beat(12)8.41%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)181.57%
Min Revenue beat(2)139.53%
Max Revenue beat(2)223.6%
Revenue beat(4)4
Avg Revenue beat(4)178.04%
Min Revenue beat(4)139.53%
Max Revenue beat(4)223.6%
Revenue beat(8)8
Avg Revenue beat(8)199.94%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.8%
PT rev (3m)10.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.24%
EPS NY rev (1m)6.92%
EPS NY rev (3m)12.65%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)147.17%
Revenue NY rev (1m)39.36%
Revenue NY rev (3m)107.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.28
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB 0.8
EV/EBITDA N/A
EPS(TTM)-2.11
EYN/A
EPS(NY)-2.83
Fwd EYN/A
FCF(TTM)-1.81
FCFYN/A
OCF(TTM)-1.77
OCFYN/A
SpS0.36
BVpS5.54
TBVpS5.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.69%
ROE -40.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.82%
ROA(5y)-34.01%
ROE(3y)-34.07%
ROE(5y)-42.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 55.32%
Cap/Sales 11.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.65
Quick Ratio 12.65
Altman-Z -0.19
F-Score4
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)232.67%
Cap/Depr(5y)247.65%
Cap/Sales(3y)257.49%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.68%
EPS Next Y-10.2%
EPS Next 2Y-9.79%
EPS Next 3Y-3.1%
EPS Next 5Y-8.01%
Revenue 1Y (TTM)174.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%479.03%
Revenue Next Year41.43%
Revenue Next 2Y-26.34%
Revenue Next 3Y-16.91%
Revenue Next 5Y-6.18%
EBIT growth 1Y-2.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.59%
EBIT Next 3Y-20.02%
EBIT Next 5YN/A
FCF growth 1Y-1.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.45%
OCF growth 3YN/A
OCF growth 5YN/A